Journals / Klinik Psikofarmakoloji Bülteni / 2000 / Cilt: 10 - Sayı: 4

Lamotrigine treatment in the management of refractory bipolar patients

Tedaviye dirençli bipolar hastalarda lamotrijin kullanımı

Pages
171–175
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: These open clinical trial data provide preliminary evidence that lamotrigine may be an effective treatment option for the patients with refractory bipolar disorder.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Antiepileptic drugs, such as carbamazepine and sodium valproate, are integral psychopharmacological therapy of bipolar disorders over the last decade.
📊
Key Findings & Data:Method : Six patients with diagnosis of bipolar affective disorder and 2 schizoaffective patients treated with lamotrigine as add-on therapy (4 patients)or monotherapy (4 patients).
💡
Conclusion & Impact:Conclusions: These open clinical trial data provide preliminary evidence that lamotrigine may be an effective treatment option for the patients with refractory bipolar disorder.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Antiepileptic drugs, such as carbamazepine and sodium valproate, are integral psychopharmacological therapy of bipolar disorders over the last decade. Lamotrigine which is a new antiepileptic drug that acts on amino acid neurotransmitters and sodium channels, has been reported to have potential mood-stabilizing effects. In this open clinical trail we aimed to investigate the role of lamotrigine in treatment of refractory bipolar patients. Method : Six patients with diagnosis of bipolar affective disorder and 2 schizoaffective patients treated with lamotrigine as add-on therapy (4 patients)or monotherapy (4 patients). Results: Six patients (5 bipolar and 1 schizoaffective) had marked or moderate improvement in the long-term treatment. No serious adverse effect was observed. Conclusions: These open clinical trial data provide preliminary evidence that lamotrigine may be an effective treatment option for the patients with refractory bipolar disorder.

Özet

Amaç: Son 10 yılda karbamazepin, sodyum-valproat gibi antiepileptik ilaçlar bipolar bozuklukların psikofarmakolojik tedavisinin bir parçası olmuşlardır. Aminoasit nörotransmiterler ve sodyum kanalları üzerinde etki gösteren yeni bir antiepileptik ilaç olan lamotrijinin potansiyel bir duygu durum dengeleyicisi olduğu bildirilmiştir. Biz bu açık, klinik çalışmada lamotrijinin tedaviye dirençli bipolar hastalarda etkinliğini araştırmayı planladık. Yöntem: Bipolar bozukluk tanısı almış 6 hasta ve şizoafektif bozukluk tanısı ile izlenen 2 hasta çalışmaya alındı. Lamotrijin hastalara almış oldukları tedavilere ek olarak (4 hasta)veya tek başına (4 hasta)verildi. Bulgular: Uzun dönem takipte altı hasta (5 bipolar ve 1 şizoafektif)tedavi ile belirgin veya orta düzeyde iyileşme gösterdi. Hastaların hiç birinde ciddi bir yan etki gözlenmedi. Sonuç: Bu açık, klinik çalışmanın verileri lamotrijinin dirençli bipolar bozukluk tanısı almış hastalar için etkili bir tedavi seçeneği olabileceği yönünde ön kanıtlar sağlamıştır.

🔖

Cite This Article

GÖNÜL, A. S., OĞUZ, A., YABANOĞLU, İ., EŞEL, E. (2022). Lamotrigine treatment in the management of refractory bipolar patients. Klinik Psikofarmakoloji Bülteni, Cilt: 10 - Sayı: 4, 171–175. https://ajindex.com/articles/574578

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Calabrase JR, Bowden CL, Woyshville MJ. Lithium and anticonvulsant in bipolar disorder. In: Bloom FE, Kupfer DJ, editors. Pschopharmacology: The fourth Generation of Progress. New York Raven Press, 1993:1099-1111
  2. Kukopolos A, Reginaldi D, Laddomada P, Floris G, Serra G, Tondo L. Course of the manic depressive cycle and changes caused by treatment. Pharmacopsychiatria 1980; 13:156-167
  3. Bauer MS, Calabrese J, Dunner DL, Post R, Whybrow PC, Gyulai L, Tay LK, Younkin SR, Bynum D, Lavori P. Multisite data reanalysis of the validity of rapid cycling as a course modifier for bipolar disorder in DSM-IV. Am J Psychiatry 1994; 151:506-515
  4. Schachter SC, Leppik E, Matsuo F, Messenheimer JA, Faught E, Risner ME. Lamotrigine: a six month placebo controlled, safety and tolerance study. J Epilepsy 1995; 8: 201-209
  5. Lang DG, Wang CM, Cooper BR. Lamotrigine, phenytoin and carbamazepine interaction on the sodium current present in N4TG1 mouse neuroblastoma cells. J Pharmacol Exp Ther 1993; 266:829-835
  6. Pellock JM. Overview of lamotrigine and the new antiepileptic drugs: the challenge. J Child Neurol 1997;12 Suppl 1:S48-52
  7. Bowden BL, Calabrase JR, Mc Elroy SL, Rhodes LJ, Paul KE, Cookson J, Anderson J, Bolden-Watson C, Ascher J, Monaghan E, Zhou J. The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder. Biol Psychiatry 1999; 45: 953-958
  8. Calabrese JR, Bowden CL, McElroy SL, Cookson J, Andersen J, Keck PE Jr, Rhodes L, Bolden-Watson C, Zhou J, Ascher JA. Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. Am J Psychiatry 1999;156:1019-1023
  9. Fogelson DL, Sternbach H. Lamotrigine treatment of Refractory Bipolar Disorder. J Clin Psychiatry 1997; 58: 271-273
  10. Hirchfeld RMA, Clayton PJ, Cohen I. Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry 1994; 15:S5-S15
  11. Mc Elroy SL, Keck PE, Pope HG. Sodium valproate: its use in primary psychiatric disorders. J Clin Psychopharmacol 1987;7:16-24
  12. Kusumakar V, Yatham LN. Lamotrigine in treatment resistant bipolar depression. Psychiatry Res 1997; 72:145- 148
  13. Berk M. Lamotrigine and the treatment of mania in bipolar disorder. Eur Neuropsychopharmacol 1999;9 Suppl 4:S119-123
  14. Ichim L, Berk M, Brook S. Lamotrigine compared with lithium in mania: a double-blind randomized controlled trial. Ann Clin Psychiatry 2000;12:5-10
  15. Physicians’ Desk Reference, 51st ed. Montvale, NJ, Medical Economi